ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C9H7Cl2N5
CAS番号:
分子量:
256.09
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI key
PYZRQGJRPPTADH-UHFFFAOYSA-N
SMILES string
Nc1nnc(c(N)n1)-c2cccc(Cl)c2Cl
InChI
1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)
grade
pharmaceutical primary standard
API family
lamotrigine
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
類似した製品をお探しですか？ 訪問 製品比較ガイド
Biochem/physiol Actions
抗けいれん薬。
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
保管分類
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
1356756-100MG: + 1356756-150MG:
jan
Effect of Permeation enhancers on diffusion of lamotrigine drug through cellophane membrane.
Rao, Vinay, et al.
American Journal of Advanced Drug Delivery, 1.4, 606-610 (2013)
Allyson K Friedman et al.
Science (New York, N.Y.), 344(6181), 313-319 (2014-04-20)
Typical therapies try to reverse pathogenic mechanisms. Here, we describe treatment effects achieved by enhancing depression-causing mechanisms in ventral tegmental area (VTA) dopamine (DA) neurons. In a social defeat stress model of depression, depressed (susceptible) mice display hyperactivity of VTA
Mary Ellen Trunko et al.
The International journal of eating disorders, 47(3), 329-334 (2013-12-18)
Some patients with symptoms of binge eating and purging are successfully treated with specific serotonin reuptake inhibitors (SSRIs), but others experience only partial or no benefit. Significant affect dysregulation and poor impulse control may be characteristics that limit responsiveness. We
Jennifer G Reid et al.
The Journal of clinical psychiatry, 74(7), 675-684 (2013-08-16)
Owing to the prevalence of medication side effects and treatment resistance, prescribers often consider off-label uses of US Food and Drug Administration (FDA)-approved agents for the treatment of persistent symptoms. The authors review the available literature on the FDA-approved and
Jacqueline A French et al.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 9(1), 176-184 (2011-12-06)
The efficacy and safety of lamotrigine extended-release tablets (LTG XR) as monotherapy for partial seizures were evaluated using the conversion-to-monotherapy design, and historical data as the control. This methodology was recently approved by the United States Food and Drug Administration
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）